PGPamela K. Ginex

Pamela K. Ginex

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pamela K. Ginex has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Healthcare Access and Utilization in a National Sample of Cancer Survivors With a History of Military Service

    by Pamela K. Ginex, Saatvik Sandal, S. Scott Jones, Giselle Gerardi

    In the United States, there are about 18 million living veterans (7% of the population) and about 1.3 million active-duty military service members (0.4% of the population) (Vespa, 2020). Veterans are aging, with the largest group of veterans being 70–74 years of age. People with a history of military service (i.e., veterans) face unique health challenges. Experiences such as exposure to toxic environments, deployment, and occupational exposure place veterans at higher risk for chronic disease such as cancer (Grier et al., 2022).

  • Open Access

    Promoting lifestyle medicine for supportive care in cancer: MASCC endorsement of the ACLM cancer risk reduction and survivorship toolkit

    by Pamela K. Ginex, Amber S. Kleckner, Sami Mansfield, Nicolas H. Hart, Nigel Brockton, Fredrick Ashbury, Niharika Dixit

    Cancer survivors face cancer and treatment-related health challenges and are at increased risk of developing other chronic diseases, often leading to multimorbidity. Lifestyle medicine can reduce the risk and severity of up to 80% of these chronic diseases and are an important component of survivorship care. Healthy lifestyle habits — such as a plant-forward diet, regular exercise, and maintaining healthy weight — improve life expectancy in a general population with compelling evidence supporting the same benefits among cancer survivors. A new resource from the American College of Lifestyle Medicine (ACLM), the Lifestyle Medicine Cancer Risk Reduction and Survivorship Toolkit (LMCT), aims to overcome barriers by providing accessible, evidence-based lifestyle medicine resources for use at the point of care. To support oncology healthcare professionals and cancer survivors, MASCC has endorsed the ACLM Cancer Risk Reduction and Survivorship Toolkit. This editorial describes the LMCT and how it can be a resource for cancer supportive care.


  • Exposure-Informed Care Following Toxic Environmental Exposures: A Lifestyle Medicine Approach

    by Pamela K. Ginex, Paul Barach, Paolo Boffetta, Jedidah T. Poole, Janeen H. Trembley, Julie Tomấška, Mark A. Klein, Tammy A. Butterick

    Exposure to environmental toxins presents substantial health risks, particularly for individuals facing heightened exposure due to occupational hazards. This analytic review highlights the critical need to address these risks through a lifestyle medicine approach, advocating for integrated care strategies to mitigate the long-term health impacts of toxic environmental exposures. We explore exposures to environmental toxins in 2 at-risk populations, military service members exposed to airborne hazards and burn pits during overseas deployments and first responders to the World Trade Center terrorist attack. The review highlights the immediate and long-term chronic health effects of toxic environmental exposures, emphasizing the variable symptoms, long latency, and long-term complex outcomes that necessitate an exposure-informed health care model. Exposure-informed care can enhance overall well-being and reduce the risks of chronic illnesses by incorporating lifestyle medicine principles supported by a learning community system. The proposed model makes recommendations for a shift to exposure-informed preventative care. This enhanced approach aims to promote a longer and healthier life for those at increased risks following toxic environmental exposures. Understanding the context of military burn pit and World Trade Center environmental exposures and the possibilities of exposure-informed care is paramount in shifting from a traditional disease-centered model to a holistic, person-centered approach.


  • Open Access

    15 years supporting adherence to oral anti-cancer treatment: use of the MASCC Oral Agent Teaching Tool (MOATT) worldwide, a review for the future

    by Sultan Kav, Mapi Fleury, Paz Fernández-Ortega, Ellen F. Manzullo, Kimberley-Ann Kerr, Regina DeGennaro, Pamela K. Ginex

    Introduction: The MASCC Oral Agent Teaching Tool (MOATT®) was developed to address the challenges of patient education and adherence in the context of oral anticancer agents. Despite its evidence-based design and global availability, there is limited documentation on its application in clinical practice and research. This review aims to assess the extent of MOATT usage and evaluate the impact on patient outcomes. Methods: A scoping review was conducted following Joanna Briggs Institute and PRISMA-ScR reporting standards. Databases included CINAHL, Embase, PsycInfo, Web of Science, and PubMed. Inclusion criteria were studies published between 2010 and 2023 that used MOATT in clinical practice or research. Two reviewers independently screened and extracted data, with discrepancies resolved by consensus. Findings: Seventeen studies met the inclusion criteria, from nine countries. The MOATT was most used by nurses and pharmacists to guide patient education when initiating new oral anticancer therapies. Reported outcomes included improved patient knowledge, understanding of medication regimens, and comfort in managing treatments. However, only six studies assessed medication adherence, with mixed results. The tool was adapted in various settings, yet there was a notable lack of detailed reports on its usage and outcomes, highlighting underutilization and potential barriers to broader implementation. Conclusion: The MOATT is a valuable tool for supporting patients on oral anticancer agents yet is underutilized in practice. Future research should focus on understanding the barriers to its adoption, exploring patient and provider perspectives, and integrating implementation science to enhance its use in diverse clinical contexts.


  • Climate change, climate disasters and oncology care: a descriptive global survey of oncology healthcare professionals

    by Milagros R. Elia, Ismail Toygar, Elaine Tomlins, Gulcan Bagcivan, Shabnam Parsa, Pamela K. Ginex

    Purpose Climate disasters and climate change have implications for healthcare globally. As the number and intensity of climate disasters increase, it is important to understand the effects on healthcare. We conducted a global survey of oncology healthcare providers to identify awareness, experiences, and educational needs related to climate change. Methods An existing climate and health survey was adapted to oncology. This IRB- approved, 30-item survey measured demographics, climate disaster awareness, effects on cancer care and educational needs. Healthcare professionals employed in oncology settings (practice, research, or academic) were eligible. The survey was disseminated via social media and professional organizations. Descriptive statistics were computed using SPSS. Results 154 responses from 26 countries were received from nurses (56%), physicians (19%), and other healthcare professionals (25%). Common climate change-related events impacting oncology care were extreme heat (63.8%) and heavy rains (52.2%). Respondents reported their workplace has a disaster plan for climate-related weather events (50.4%) or has taken steps to prepare for a climate-related weather event (48.5%). Respondents were aware that the planet has warmed significantly (98.7%), that healthcare contributes to greenhouse gas emissions (98.6%) and reported wanting to learn more about how climate change affects cancer care (88.3%). Preferred educational modalities include webinars (69%), e-learning (55%), journal articles (48.3%), conferences (46.3%) and podcasts (38.9%). Conclusions This global survey is the first to identify the awareness, experiences, and educational needs of oncology healthcare professionals related to climate change and climate disasters. Healthcare providers are positioned to take leadership roles related to climate and health.


  • Open Access

    Reduction of head and neck cancer risk following smoking cessation: a systematic review and meta-analysis

    by Malak Khalifeh, Pamela Ginex, Paolo Boffetta

    Objective Head and neck (HN) cancer comprises the neoplasms originating from the oral cavity, pharynx and larynx. We aimed at reviewing the available literature on the effect of smoking cessation on HN cancer risk. Method We conducted a systematic search in Medline, PubMed and Embase to June 2022. We abstracted or calculated relative risks (RR) and 95% CIs of HN cancer after cessation of tobacco smoking (both former smoking status and duration of quitting) and combined them using random effects meta-analyses. Papers included were case–control or cohort studies available in the English language. Studies investigating smoking cessation after cancer diagnosis, case reports, intervention studies or animal studies were excluded. Quality and susceptibility to bias of each included study were evaluated using the Newcastle-Ottawa Scale. Publication bias was assessed using funnel plot and Egger’s test. Results A total of 65 studies were included in the review, including 5 cohort and 60 case–control studies. The RR of HN cancer for former smokers compared with current smokers was 0.40 (95% CI 0.35 to 0.46). In an analysis by cancer site, the RR of oral cancer was 0.44 (95% CI 0.35 to 0.55), that of pharyngeal cancer 0.44 (95% CI 0.32 to 0.60) and that of laryngeal cancer 0.38 (95% CI 0.29 to 0.50). The dose-response meta-analysis was based on 37 studies. The RR per 10-year increase in smoking cessation was 0.47 (95% CI 0.43 to 0.52). Conclusions The risk of HN cancer declines within the first 5 years of quitting smoking. Quitting smoking is an essential element of HN cancer prevention. Trial registration number The protocol has been deposited in the PROSPERO repository (CRD42022338262).


  • Physical activity interventions for cancer-related fatigue: A scoping review of randomized controlled trials from a Nursing Science Precision Health Model perspective

    by Pamela K. Ginex, Sylvia K. Wood, Kapeena Sivakumaran, Ifeoluwa Babatunde, Tiffany Yu, Karen DiValerio Gibbs, Rebecca L. Morgan


  • Open Access

    Gross Hematuria and Lower Urinary Tract Symptoms Associated With Military Burn Pits Exposures in US Veterans Deployed to Iraq and Afghanistan

    by Mosammat M. Perveen, Henry E. Mayo-Malasky, Mary F. Lee-Wong, Julie M. Tomaska, Edward Forsyth, Amy Ma Gravely, Mark A. Klein, Janeen H. Trembley, Tammy A. Butterick, Robert A. Do Promisloff, et al.

    Objective: The aim of the study is to describe rates of hematuria and other lower urinary tract symptoms, including self-reported cancer rates, among veterans postburn pits emissions exposure during deployment to Iraq and Afghanistan. Methods: US post-9/11 veterans with burn pits emissions exposure confirmed via DD214 forms in the Burn Pits360.org Registry were sent a modified survey. Data were deidentified and anonymously coded. Results: Twenty-nine percent of the 155 respondents exposed to burn pits self-reported seeing blood in their urine. The average index score of our modified American Urological Association Symptom Index Survey was 12.25 (SD, 7.48). High rates of urinary frequency (84%) and urgency (76%) were self-reported. Bladder, kidney, or lung cancers were self-reported in 3.87%. Conclusions: US veterans exposed to burn pits are self-reporting hematuria and other lower urinary tract symptoms.


  • Climate disasters and oncology care: a systematic review of effects on patients, healthcare professionals, and health systems

    by Pamela Ginex, Erin Dickman, Milagros R. Elia, Darcy Burbage, Ryne Wilson, Jessica A. Koos, Kapeena Sivakumaran, Rebecca L. Morgan

    Purpose Climate disasters have devastating effects on communities and society that encompass all aspects of daily life, including healthcare. Patients with cancer are particularly vulnerable when disaster strikes. As the number and intensity of disasters increases, it is important to understand the effects across the cancer care continuum. This systematic review investigates the effect of climate disasters on patients, the oncology healthcare workforce, and healthcare systems. Methods A medical librarian conducted a literature search in PubMed, Embase, CINAHL, and Web of Science from January 1, 2016, through May 11, 2022. Eligible studies included any published report on a climate disaster globally reporting on patient-, oncology healthcare workforce-, or healthcare systems-level outcomes. Study quality was assessed, and findings were narratively synthesized, given the diversity of reported evidence. Results The literature search identified 3618 records, of which 46 publications were eligible for inclusion. The most frequent climate disaster was hurricanes (N = 27) followed by tsunami (N = 10). Eighteen publications were from disasters that occurred in the mainland USA with 13 from Japan and 12 from Puerto Rico. Patient-level outcomes included treatment interruptions and inability to communicate with the healthcare team. At the workforce level, findings included distressed clinicians caring for others when their own lives have been affected by a disaster along with lack of disaster preparedness training. Health systems reported closures or shifting services post-disaster and a need to have improved emergency response plans. Conclusion Response to climate disasters necessitates a holistic approach at the patient, workforce, and health systems levels. Specifically, interventions should focus on mitigating interruptions in care for patients, advanced coordination and planning for workforce and health systems, and contingency planning for allocation of resources by health systems.


  • ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications

    by Sarah M. Belcher, Emily Mackler, Benyam Muluneh, Pamela K. Ginex, Mary K. Anderson, Elizabeth Bettencourt, Ryan K. DasGupta, Jennifer Elliott, Erica Hall, Michelle Karlin, et al.

    Oral anticancer medications (OAMs) have changed the oncology treatment landscape for patients and clinicians. OAM use is growing annually, accounting for 40%–50% of new cancer treatments in development (U.S. Food and Drug Administration, 2021). Shifting treatment from a controlled clinical setting to a patient’s home has advantages paired with potential challenges for the patient and healthcare team.